AstraZeneca to acquire Amolyt Pharma,
expanding late-stage rare disease pipeline
PUBLISHED14 March 2024
Amolyt development portfolio includes Phase III asset with potential to address
significant unmet need in patients with chronic hypoparathyroidism
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond
complement inhibition, building on company’s success in bone metabolism and
opportunity in rare endocrinology
https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html
- Forums
- ASX - By Stock
- Merck to acquire Prometheus in a US$ 10.8 b deal
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B |
Open | High | Low | Value | Volume |
$20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 782 | $20.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.72 | 1021 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 782 | 20.610 |
2 | 3495 | 20.600 |
2 | 649 | 20.590 |
2 | 1774 | 20.570 |
1 | 145 | 20.550 |
Price($) | Vol. | No. |
---|---|---|
20.720 | 1021 | 2 |
20.730 | 5256 | 1 |
20.750 | 2517 | 1 |
20.790 | 782 | 1 |
20.800 | 649 | 2 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online